Background. Data from the phase 3, randomized, multicentre PALETTE clinical trial led to the approval of pazopanib as an option for the treatment of patients with chemoresistant soft tissue sarcoma (STS). Presumably, the results of a registration study and data obtained in the course of practical application may differ due to the heterogeneity of patients and varying degrees of pretreatment.
Objective. Comparison of the results of the phase 3 registration PALETTE study with the results obtained in the framework of our own clinical practice.
Methods. We analyzed data from 38 patients who received pazopanib for STS of various histological subtypes in the dissemination stage at the N.N. Petrov National Research Center of Oncology in the period from 2013 to 2021. The end point of the study was progression-free survival (PFS).
Results. The most common morphological subtype of STS was leiomyosarcoma (39.5%). Pazopanib was started after progression on 2–4 different drug regimens. The duration of treatment varied from 0.9 to 68.9 months. The median PFS was 4.0 months.
Conclusion. The data obtained are comparable with those of the international PALETTE clinical trial, which confirms the efficacy of pazopanib in this cohort of patients.

Keywords: pazopanib, metastatic soft tissue sarcoma, real clinical practice, targeted therapy